Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis

This research should be replicated for stroke patients but that won't occur because we have NO strategy and NO leadership following up anything interesting in research. Or you could illegally ask your doctor to get this from Germany.
http://tan.sagepub.com/content/9/1/9?etoc

1. Uwe K. Zettl⇑
   1. Department of Neurology, University of Rostock, Gehlsheimer Straße 20, D-18147 Rostock, Germany
2. Paulus Rommer
   1. Department of Neurology, University of Rostock, Germany
   2. Department of Neurology, Medical University of Vienna, Austria
3. Petra Hipp
   1. Saproma, Roetgen, Germany
4. Robert Patejdl
   1. Department of Neurology, University of Rostock, Germany Oscar-Langendorff-Institute of Physiology, University of Rostock, Germany

1. uwe.zettl@med.uni-rostock.de

Abstract

Spasticity, one of the main symptoms of multiple sclerosis (MS), can affect more than 80% of MS patients during the course of their disease and is often not treated adequately. δ-9-Tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray is a plant-derived, standardized cannabinoid-based oromucosal spray medicine for add-on treatment of moderate to severe, resistant multiple sclerosis-induced spasticity. This article reviews the current evidence for the efficacy and safety, with dizziness and fatigue as the most common treatment-related adverse events, being mostly mild to moderate in severity. Results from both randomized controlled phase III studies involving about,1600 MS patients or 1500 patient-years and recently published studies on everyday clinical practice involving more than 1000 patients or more than,1000 patient-years are presented.